Cannabis and Cannabinoids for Chronic Pain
- 2.5k Downloads
Purpose of Review
The purpose of this study was to provide the most up-to-date scientific evidence of the potential analgesic effects, or lack thereof, of the marijuana plant (cannabis) or cannabinoids, and of safety or tolerability of their long-term use.
We found that inhaled (smoked or vaporized) cannabis is consistently effective in reducing chronic non-cancer pain. Oral cannabinoids seem to improve some aspects of chronic pain (sleep and general quality of life), or cancer chronic pain, but they do not seem effective in acute postoperative pain, abdominal chronic pain, or rheumatoid pain. The available literature shows that inhaled cannabis seems to be more tolerable and predictable than oral cannabinoids.
Cannabis or cannabinoids are not universally effective for pain. Continued research on cannabis constituents and improving bioavailability for oral cannabinoids is needed. Other aspects of pain management in patients using cannabis require further open discussion: concomitant opioid use, medical vs. recreational cannabis, abuse potential, etc.
KeywordsMarijuana Medicinal marijuana Medical marijuana Medicinal cannabis Medical cannabis Recreational marijuana Recreational cannabis
The authors would like to thank Dr. Jack E. Fincham for his thorough review, critical comments, and editorial suggestions, and to Ms. Rachel Grosick for her careful review and editorial suggestions.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S. Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction. 2017; https://doi.org/10.1111/add.13910.
- 5.Schatman ME. Medical marijuana: the state of the science. Medscape. 2015 Feb 6. http://www.medscape.com/viewarticle/839155
- 8.Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug Alcohol Depend. 2017;175:67–76. https://doi.org/10.1016/j.drugalcdep.2017.02.003.CrossRefPubMedGoogle Scholar
- 9.Wilsey BL, Deutsch R, Samara E, Marcotte TD, Barnes AJ, Huestis MA, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res. 2016;9:587–98. https://doi.org/10.2147/JPR.S113138.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.FDA. Draft guidance on dronabinol. 2014. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm199636.pdf.
- 11.INCAN INdCMyNSZ. Revisión bibliográfica: cannabinoides en dolor no oncológico. 2014. http://www.dolorypaliativos.org/art131.asp.
- 12.• GW P. GW pharmaceuticals and otsuka announce results from two remaining sativex(r) phase 3 cancer pain trials. 2015. https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-and-otsuka-announce-results-first-three-sativex%C2%AE-phase-3-cancer. This press release announced the lack of difference between nabiximols vs. placebo for pain intensity in patients with cancer chronic pain. This announcement is in contrast with previous results which show promising data of this cannabinoid preparation for this condition.
- 13.GW P. GW’s epidiolex® clinical program. 2015. https://www.gwpharm.com/epilepsy-patients-caregivers/patients.
- 14.Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM, et al. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain. 2014;30(6):472–8. https://doi.org/10.1097/AJP.0000000000000022.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Newmeyer MN, Swortwood MJ, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabis edibles: blood and oral fluid cannabinoid pharmacokinetics and evaluation of oral fluid screening devices for predicting delta9-tetrahydrocannabinol in blood and oral fluid following cannabis brownie administration. Clin Chem. 2017;63(3):647–62. https://doi.org/10.1373/clinchem.2016.265371.CrossRefPubMedGoogle Scholar
- 19.•• National Academies of Sciences E, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, D.C: National Academies Press. 10.17226/24625. 2017. This study is the most comprehensive and up-to-date document that evaluates and qualifies the scientific evidence of the majority of the clinical uses of cannabis or cannabinoids. The report shows that the most clear evidence for medicinal cannabis is for the treatment of chronic pain.
- 20.• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73. https://doi.org/10.1001/jama.2015.6358. This study provides supportive evidence on the efficacy of cannabis or cannabinoids for the treatment of pain and other conditions. CrossRefPubMedGoogle Scholar
- 21.•• Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16(12):1221–32. https://doi.org/10.1016/j.jpain.2015.07.009. This study provides thorough evidence in favor of inhaled cannabis for the treatment of chronic non-cancer pain. CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–21. https://doi.org/10.1212/01.wnl.0000253187.66183.9c.CrossRefPubMedGoogle Scholar
- 27.• Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16(7):616–27. https://doi.org/10.1016/j.jpain.2015.03.008. This study shows that low THC concentrations (1 - 4%) of vaporized cannabis are effective to reduce painful diabetic neuropathy. CrossRefPubMedPubMedCentralGoogle Scholar
- 28.• Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17(9):982–1000. https://doi.org/10.1016/j.jpain.2016.05.010. This study demonstrates that low THC concentrations (2.9–6.7%) of vaporized cannabis are effective to reduce chronic pain after spinal cord injury or disease. CrossRefPubMedPubMedCentralGoogle Scholar
- 29.• Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017; https://doi.org/10.1213/ANE.0000000000002110. This study shows that oral cannabinoids are modestly effective to reduce chronic pain, but they improve other aspects of chronic pain, such as quality of life or sleep. This analysis also shows some limitations of oral cannabinoids: reduced tolerability.
- 31.Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336(7637):199–201. https://doi.org/10.1136/bmj.39429.619653.80.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–97. https://doi.org/10.1007/s00415-012-6739-4.CrossRefPubMedGoogle Scholar
- 33.Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manag. 2014;47(1):166–73. https://doi.org/10.1016/j.jpainsymman.2013.02.018.CrossRefGoogle Scholar
- 34.Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20. https://doi.org/10.1016/j.pain.2007.08.028.CrossRefPubMedGoogle Scholar
- 35.Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812–9. https://doi.org/10.1212/01.wnl.0000176753.45410.8b.CrossRefPubMedGoogle Scholar
- 36.Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33(1):128–30. https://doi.org/10.2337/dc09-1029.CrossRefPubMedGoogle Scholar
- 37.Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012. https://doi.org/10.1002/j.1532-2149.2013.00445.x.CrossRefPubMedGoogle Scholar
- 39.Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153(10):2073–82. https://doi.org/10.1016/j.pain.2012.06.024.CrossRefPubMedGoogle Scholar
- 41.• CADTH CAfDaTH. Cannabinoid buccal spray for chronic non-cancer or neuropathic pain: a review of clinical effectiveness, safety, and guidelines. Otawa (ON); 2016. This study concluded that there is no sufficient evidence to support the use of oromucosal cannabinoids for the treatment of chronic pain, and shows the conflicting results available in the literature for this form of administration. Google Scholar
- 42.Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167–79. https://doi.org/10.1016/j.jpainsymman.2009.06.008.CrossRefGoogle Scholar
- 43.Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49. https://doi.org/10.1016/j.jpain.2012.01.003.CrossRefPubMedGoogle Scholar
- 44.• Fitzcharles MA, Ste-Marie PA, Hauser W, Clauw DJ, Jamal S, Karsh J, et al. Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Care Res (Hoboken). 2016;68(5):681–8. https://doi.org/10.1002/acr.22727. Despite the limited number of studies on this topic, this review shows that oral cannabinoids do not reduce pain related to rheumatoid conditions. CrossRefGoogle Scholar
- 45.Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50–2. https://doi.org/10.1093/rheumatology/kei183.CrossRefGoogle Scholar
- 46.Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837–46. https://doi.org/10.1016/j.pain.2012.04.020.CrossRefPubMedGoogle Scholar
- 50.• de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H, Pain, et al. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15(7):1079–86 e4. https://doi.org/10.1016/j.cgh.2016.09.147. Despite the limited number of studies on this topic, this study shows that oral cannabinoids are not effective to treat chronic abdominal pain related to surgery or pancreatitis. CrossRefPubMedGoogle Scholar
- 55.•• Ware MA, Wang T, Shapiro S, Collet JP, team Cs. Cannabis for the Management of Pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233–42. https://doi.org/10.1016/j.jpain.2015.07.014. This is the only controlled (open label) study that has assessed the safety and tolerability of cannabis used for 1 year in subjects with chronic non-cancer pain. It shows that cannabis seems to be tolerable and relatively safe when used long-term. CrossRefPubMedGoogle Scholar
- 56.Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9. https://doi.org/10.1136/jnnp.2005.070136.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manag. 2013;46(2):207–18. https://doi.org/10.1016/j.jpainsymman.2012.07.014.CrossRefGoogle Scholar